Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Fig. 1

Treatment differences in MACE and MACE components in SUSTAIN 6. Analysis of time from randomization to first event adjudication committee-confirmed event. Subjects were censored at their planned end-of-trial visit, last direct subject-site contact or all-cause death of the subject, whichever occurred first. Estimated HRs and associated CIs are from a Cox proportional hazards model with an interaction between treatment (semaglutide, placebo) and subgroups as fixed factors. The p-values are 2-sided for test for heterogeneity of treatment between subgroups. CI confidence interval, CV cardiovascular, CVD cardiovascular disease, HR hazard ratio, MI myocardial infarction

Back to article page